273 related articles for article (PubMed ID: 25000213)
1. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies.
Jackson VM; Price DA; Carpino PA
Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213
[TBL] [Abstract][Full Text] [Related]
2. Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
Srivastava G; Apovian C
Curr Obes Rep; 2018 Jun; 7(2):147-161. PubMed ID: 29504049
[TBL] [Abstract][Full Text] [Related]
3. Anti-obesity drugs: a review about their effects and their safety.
Derosa G; Maffioli P
Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
[TBL] [Abstract][Full Text] [Related]
4. Latest approaches for the treatment of obesity.
Jackson VM; Breen DM; Fortin JP; Liou A; Kuzmiski JB; Loomis AK; Rives ML; Shah B; Carpino PA
Expert Opin Drug Discov; 2015; 10(8):825-39. PubMed ID: 25967138
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
Correia ML; Haynes WG
Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333
[TBL] [Abstract][Full Text] [Related]
6. New drug targets for the treatment of obesity.
Powell AG; Apovian CM; Aronne LJ
Clin Pharmacol Ther; 2011 Jul; 90(1):40-51. PubMed ID: 21654742
[TBL] [Abstract][Full Text] [Related]
7. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance.
Aronne LJ; Finer N; Hollander PA; England RD; Klioze SS; Chew RD; Fountaine RJ; Powell CM; Obourn JD
Obesity (Silver Spring); 2011 Jul; 19(7):1404-14. PubMed ID: 21293451
[TBL] [Abstract][Full Text] [Related]
9. The obesity epidemic: current and future pharmacological treatments.
Hofbauer KG; Nicholson JR; Boss O
Annu Rev Pharmacol Toxicol; 2007; 47():565-92. PubMed ID: 17002599
[TBL] [Abstract][Full Text] [Related]
10. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
11. Two anti-obesity hopefuls and their safety.
Bello NT; Campbell SC
Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
[No Abstract] [Full Text] [Related]
12. [Drug treatment of obesity--current situation and perspectives].
Hainer V
Cas Lek Cesk; 2010; 149(11):513-9. PubMed ID: 21391349
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk of obesity: defining the role of weight loss drugs.
Ling H; Lenz TL; Burns TL; Hilleman DE
Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
[TBL] [Abstract][Full Text] [Related]
14. New and emerging drug molecules against obesity.
George M; Rajaram M; Shanmugam E
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological therapies for obesity.
Kaplan LM
Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for the treatment of obesity.
Martinussen C; Bojsen-Moller KN; Svane MS; Dejgaard TF; Madsbad S
Expert Opin Emerg Drugs; 2017 Mar; 22(1):87-99. PubMed ID: 27927032
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy of obesity: an update.
Schurgin S; Siegel RD
Nutr Clin Care; 2003; 6(1):27-37. PubMed ID: 12841428
[TBL] [Abstract][Full Text] [Related]
18. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the pathophysiology and pharmacological treatment of obesity.
Chugh PK; Sharma S
J Clin Pharm Ther; 2012 Oct; 37(5):525-35. PubMed ID: 22462645
[TBL] [Abstract][Full Text] [Related]
20. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
Kennett GA; Clifton PG
Pharmacol Biochem Behav; 2010 Nov; 97(1):63-83. PubMed ID: 20688100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
